Keaton T Cameron-Burr1, Albert Conicella2, Mark J Neavyn1. 1. Division of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA. 2. Division of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA. albert.conicella@umassmemorial.org.
Abstract
INTRODUCTION: The USA is in an opioid epidemic, with an increased number of individuals taking psychoactive drugs while executing the tasks of everyday life, including operating a motor vehicle. The pharmacology of opioids has been widely studied, but the effects of opioids on psychomotor function, driving performance, and the risk of motor vehicle collision remain less clear. Clinicians are faced with the challenge of controlling patient pain while also reconciling conflicting messages from the literature about how safe it is for their patients taking opioids to engage in potentially dangerous routine tasks. DISCUSSION: This review assesses the current literature regarding opioids as they relate to neurocognitive function, driving performance, and accident risk. Manuscripts are categorized by study context and subject matter: controlled experimental administration, illicit use, prescription use, retrospective forensic toxicology, and polydrug consumption. CONCLUSION: Illicit use, initiation of therapy, and opioid use in combination with other psychoactive medications are contexts most clearly associated with impairment of driving-related functions and/or operation of a motor vehicle. Clinicians should counsel patients on the risk of impairment when initiating therapy, when co-prescribing opioids and other psychoactive drugs, or when a patient is suspected of having an opioid use disorder.
INTRODUCTION: The USA is in an opioid epidemic, with an increased number of individuals taking psychoactive drugs while executing the tasks of everyday life, including operating a motor vehicle. The pharmacology of opioids has been widely studied, but the effects of opioids on psychomotor function, driving performance, and the risk of motor vehicle collision remain less clear. Clinicians are faced with the challenge of controlling patient pain while also reconciling conflicting messages from the literature about how safe it is for their patients taking opioids to engage in potentially dangerous routine tasks. DISCUSSION: This review assesses the current literature regarding opioids as they relate to neurocognitive function, driving performance, and accident risk. Manuscripts are categorized by study context and subject matter: controlled experimental administration, illicit use, prescription use, retrospective forensic toxicology, and polydrug consumption. CONCLUSION: Illicit use, initiation of therapy, and opioid use in combination with other psychoactive medications are contexts most clearly associated with impairment of driving-related functions and/or operation of a motor vehicle. Clinicians should counsel patients on the risk of impairment when initiating therapy, when co-prescribing opioids and other psychoactive drugs, or when a patient is suspected of having an opioid use disorder.
Authors: Catherine A Marco; Dennis Mann; Jordan Rasp; Michael Ballester; Oswald Perkins; Michael B Holbrook; Kyle Rako Journal: Am J Emerg Med Date: 2017-11-08 Impact factor: 2.469
Authors: Lynette A Menefee; Evan D Frank; Canice Crerand; Shailen Jalali; John Park; Kim Sanschagrin; Marcus Besser Journal: Pain Med Date: 2004-03 Impact factor: 3.750
Authors: Olaf H Drummer; Jim Gerostamoulos; Helen Batziris; Mark Chu; John Caplehorn; Michael D Robertson; Philip Swann Journal: Accid Anal Prev Date: 2004-03
Authors: James M Bjork; Lori Keyser-Marcus; Jasmin Vassileva; Tatiana Ramey; David C Houghton; F Gerard Moeller Journal: Psychiatry Res Date: 2022-05-01 Impact factor: 11.225
Authors: Emily K Acton; Sean Hennessy; Colleen M Brensinger; Warren B Bilker; Todd A Miano; Sascha Dublin; John R Horn; Sophie Chung; Douglas J Wiebe; Allison W Willis; Charles E Leonard Journal: Front Pharmacol Date: 2022-05-10 Impact factor: 5.988